These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 327758)

  • 21. [Carbohydrate tolerance, serum insulin and triglycerides in coronary disease].
    Dobrev DG; Ilkov A
    Vutr Boles; 1975; 14(6):11-22. PubMed ID: 1224616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in glucose tolerance and plasma insulin during lipid-lowering treatment with diet, clofibrate and niceritrol.
    Lithell H; Vessby B; Hellsing K
    Atherosclerosis; 1982 Jun; 43(2-3):177-84. PubMed ID: 7052096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin and clofibrate in maturity onset diabetes mellitus: advantages of combined treatment.
    De Silva SR; Betteridge DJ; Shawe JE; Cudworth AG; Alberti KG
    Diabete Metab; 1979 Sep; 5(3):223-9. PubMed ID: 574098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clofibrate-induced changes in glucagon and insulin secretion in patients with angiographically documented coronary artery disease.
    Eaton RP; Schade DS; Lueker R
    Am J Clin Nutr; 1977 Dec; 30(12):2068-77. PubMed ID: 930877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region.
    Br Med J; 1971 Dec; 4(5790):767-75. PubMed ID: 4943605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
    Gürlek A; Bayraktar M; Kirazli S
    Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Independence of myocardial disease in the JCR:LA-corpulent rat on plasma cholesterol concentration.
    Russell JC; Koeslag DG; Amy RM; Dolphin PJ
    Clin Invest Med; 1991 Aug; 14(4):288-95. PubMed ID: 1782727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of ankle ststolic pressure measurements in patients with intermittent claudication being treated with clofibrate.
    Postlethwaite JC; Dormandy JA
    Ann Surg; 1975 Jun; 181(6):799-802. PubMed ID: 1138629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of clofibrate therapy on the glucagon and insulin secretion as well as on the glucose tolerance in patients with type IV hyperlipoproteinemia].
    Drost H; Grüneklee D; Korthaus G; Gries FA
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():835-8. PubMed ID: 1029295
    [No Abstract]   [Full Text] [Related]  

  • 30. Blood pressure, cigarette smoking and heart attack in the WHO co-operative trial of clofibrate.
    Green KG; Heady A; Oliver MF
    Int J Epidemiol; 1989 Jun; 18(2):355-60. PubMed ID: 2767848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.
    Daubresse JC; Daigneux D; Bruwier M; Luyckx A; Lefebvre PJ
    Br J Clin Pharmacol; 1979 Jun; 7(6):599-603. PubMed ID: 380614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrapulmonary administration of natural honey solution, hyperosmolar dextrose or hypoosmolar distill water to normal individuals and to patients with type-2 diabetes mellitus or hypertension: their effects on blood glucose level, plasma insulin and C-peptide, blood pressure and peaked expiratory flow rate.
    Al-Waili N
    Eur J Med Res; 2003 Jul; 8(7):295-303. PubMed ID: 12911866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of clofibrate and sulfinpyrazone on platelet survival time in coronary artery disease.
    Steele P; Battock D; Genton E
    Circulation; 1975 Sep; 52(3):473-6. PubMed ID: 1157247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of clofibrate on glucose tolerance in patients with coronary heart disease.
    Ruzyllo E; Szostak WB; Cybulska B
    Pol Arch Med Wewn; 1972 Feb; 49(2):121-3. PubMed ID: 4670209
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of treatment with a bile-sequestering agent (Secholex) on intestinal absorption, duodenal bile acids, and plasma lipids.
    Ritland S; Fausa O; Gjone E; Blomhoff JP; Skrede S; Lanner A
    Scand J Gastroenterol; 1975; 10(8):791-800. PubMed ID: 173015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Relation between concentrations of lipids, carbohydrates, fibrinogen and thyroid hormone and insulin levels in the blood of patients with chronic forms of ischemic heart disease].
    Dudaev VA; Gorin VV; Torkhovskaia TI; Ivanov AS
    Kardiologiia; 1984 Aug; 24(8):85-9. PubMed ID: 6387248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The significance of insulin resistance and hyperlipidemia in microvascular angina (syndrome X)].
    Langes K; Volk C; Schneider MA; Koschyk DH; Rinninger F; Nienaber CA
    Z Kardiol; 1995 Mar; 84(3):180-9. PubMed ID: 7732710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.
    Carlson LA; Rosenhamer G
    Acta Med Scand; 1988; 223(5):405-18. PubMed ID: 3287837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance.
    Howard BV; Hsia J; Ouyang P; Van Voorhees L; Lindsay J; Silverman A; Alderman EL; Tripputi M; Waters DD
    Circulation; 2004 Jul; 110(2):201-6. PubMed ID: 15226212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of clofibrate on progression of coronary disease: a prospective angiographic study in man.
    Cohn K; Sakai FJ; Langston MF
    Am Heart J; 1975 May; 89(5):591-8. PubMed ID: 1091127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.